top of page
Header.png

Avelo Takes Part in ‘BreathForDx’, a EUR 3M Horizon Project Revolutionizing Respiratory Diagnosis


Avelo Board of Directors: Dr. Helge Lubenow and Dr. Wolfgang Mach

May 13, 2024. Avelo joins forces with esteemed research partners from the University Hospital Heidelberg (UKHD), Ospedale San Raffaele, Desmond Tutu Health Foundation, and the National Institute of Pulmonology Marius Nasta, to revolutionize respiratory infection diagnosis in a EUR 3 million project funded under the Horizon Europe framework and co-funded by the State Secretariat for Education, Research, and Innovation (SERI).


To find out more about the project and the impact it could have on patients, click here.


About Avelo

Avelo AG, the Swiss breath aerosol diagnostic company, aims to revolutionize the diagnosis of Tuberculosis and lower respiratory tract infections causing pneumonia. Its breath collector enables non-invasive collection of pathogens from breath and works with existing PCR tests. The collector is designed for broad utility, similar to other sample collection technologies such as blood tubes. Avelo has a talented team experienced in business development, functional materials, product development, clinical research, molecular diagnostics, quality and regulatory, and is based in Zurich-Schlieren.



Yorumlar


bottom of page